68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University First Hospital
About this trial
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET/CT imaging in clear cell renal cell carcinoma patients. It will also learn about the safety, tolerability and radiation dosimetry of 68Ga-C1.
Researchers will compare the diagnostic value of 68Ga-C1 PET/CT and 18F-FDG PET/CT in Chinese patients with indeterminate renal masses or confirmed clear cell renal cell carcinoma.
Eligibility criteria
Qualifiers
Signed written informed consent；
Age ≥18；
Patients with confirmed or suspected clear cell renal cell carcinoma;
Expected survival ≥6 months.
Disqualifiers
Renal mass is known to be a metastasis of another primary tumor;
Have other malignancies that require treatment;
Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks;
Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m²;
Trial design
Treatments tested in this trial
- 68Ga-C1
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov